Linked Life Data

6151483

Source:http://linkedlifedata.com/resource/pubmed/id/6151483

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1985-3-5
pubmed:abstractText
The Beta-Blocker Heart Attack Trial (BHAT) was a multicentered, double-blind, randomized, placebo-controlled clinical trial designed to test the efficacy of long-term therapy with propranolol given to survivors of an acute myocardial infarction (MI). Three thousand, eight hundred and thirty-seven men and women, aged 30-69 years, were randomized into either the propranolol or placebo group 5 to 21 days after hospital admission for the MI and were followed at quarterly visits for 12 to 40 months (mean = 25 months). The primary outcome for the trial was all-cause mortality. This article describes the design and baseline findings of the trial. Included is a description of the historical background for the trial and the procedures employed in patient recruitment, randomization, treatment and follow-up. Also included is a comparison between the BHAT population and post-myocardial infarction patients enrolled in the other long-term trials of beta-blockers.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0197-2456
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
382-437
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1984
pubmed:articleTitle
Beta-blocker heart attack trial: design, methods, and baseline results. Beta-blocker heart attack trial research group.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Randomized Controlled Trial